SEC Form 4 · accession 0000899243-17-018550
Calithera Biosciences, Inc. · CALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Orford
Officer — SR. VP, CLINICAL DEVELOPMENT
Period of report
Jul 17, 2017
Accepted (ET)
Jul 19, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001496671
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jul 17, 2017 | S | 2,120 | $18.3126 | D | 6,879 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule10b5-1 Trading Plan adopted on June 16, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.90 to $18.675, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3Includes 6,879 shares acquired under the Company's 2014 Employee Stock Purchase Plan on May 13, 2016, November 15, 2016 and June 9, 2017.